With over 15 years of healthcare investor relations experience combined with prior banking roles, Stephanie provides strategic communications counsel to emerging biotechnology and specialty pharmaceutical companies, both pre- and post-IPO. She combines deep knowledge of the life sciences sector and the investment community to serve as a trusted IR partner for C-suite executives.
Stephanie invests the resources to be well versed in each health care client’s corporate strategy and competitive position in order to develop customized programs to raise visibility for the science and growth strategy. Since 2000, she has collaborated with the management teams at such healthcare companies as Intrexon, Clarus Therapeutics, MonoSol Rx, Compugen, Sinovac, Argos Therapeutics, Sirna Therapeutics, Transcept, NeurogesX, and BioFire Diagnostics, to name just a few.
Prior to joining ICR, Stephanie was a Senior Vice President of Investor Relations at The Ruth Group, an Assistant Vice President Morgen-Walke Associates, and a Senior Associate at The Financial Relations Board. Earlier, Stephanie held positions at Alliance Capital Management, Bankers Trust and the Federal Reserve Bank of New York. She earned a BA in Economics and International Relations from Smith College and an MBA in Finance and International Business from New York University’s Stern School of Business.